PMDAapproval72% confidence
[SHINSA]List of Approved Drugs: April 2004 to February 2026
Source: PMDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to YARTEMLEA.
Regulatory Analysis
PMDA document relevant to the signal.
Supporting Context
- Therapeutic area
- Hematology · Thrombotic Microangiopathy
- Sub-indication
- General
Related signal: FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA